At the 61st ASH Annual Meeting & Exposition, Massimo Breccia, Sapienza University of Rome, discusses discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia.
1. What is the rationale for discontinuing tyrosine-kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML)? (0:05)
2. Following discontinuation of TKIs in patients with CML, when are relapses most likely to occur? (1:20)
3. What are the current recommendations for monitoring patients following TKI discontinuation? (1:40)
4. What factors predict which patients are likely to relapse? (2:39)
5. Could you tell us a little about your study, its findings and their implications? (3:24)
Massimo Breccia has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Related Videos In Leukaemia
Courtney DiNardo, EHA 2020: Venetoclax plus Azacitadine in AML and the VIALE-A Study
Dr Courtney DiNardo (The University of Texas MD Anderson Cancer Center, Houston, United States) joins touchONCOLOGY to discuss the key findings from the VIALE-A study and the safety and efficacy of venetoclax plus azacitadine in patients with acute myeloid leukaemia and (NCT02203773 and NCT02287233.) Questions 1. What are the limitations of current therapeutic options for […]
Mikkael Sekeres, ASCO20: New combination therapy in patients with MDS/CMML or LB AML
It was a pleasure to speak to Mikkael Sekeres to discuss the presentation of the phase II study of pevonedistat + azacitidine versus azacitidine in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia (Clinicaltrials.gov identifier: NCT02610777). Questions 1. What are the limitations of hypomethylating agents such as, 5-azacitidine in the treatment […]
Othman Al Sawaf, ASCO20: Results of the Phase III CLL14 Trial for Chronic Lymphocytic Leukaemia
We were delighted to speak to Othman Al-Sawaf to discuss the data presented at ASCO20 Virtual Scientific Programme on the phase III CLL14 trial, which found that the BCL2 inhibitor venetoclax plus the monoclonal antibody obinutuzumab prolonged progression-free survival vs obinutuzumab and chlorambucil in patients with previously untreated chronic lymphocytic leukemia and coexisting conditions. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!